Partner With Us
Fueling the translation of our mRNA platform
Chief Executive Officer
Chief Medical Officer
Chief Legal Officer
Chief Human Resources Officer
Senior Vice President, Research and Process Development
Chief Business Officer
Chief Technical Officer
Chief Financial Officer
Chief Scientific Officer
Dan joined our board of directors in 2012 with more than 25 years of experience serving in management positions in the biotechnology and pharmaceutical industries. Dan spent nearly five years at ImClone Systems, serving as chief executive officer and chief financial officer. As CEO, Dan led ImClone through a significant turnaround, helping to restore the company’s reputation and to secure FDA approval of ERBITUX® (Cetuximab), a novel cancer treatment. As CFO, Dan led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, Dan served in various financial positions at Bristol-Myers Squibb over a 15-year tenure.
Dan has advised and served as executive chair or member of the board of directors for a number of private biopharmaceutical companies, including Stromedix, Inc. (until its acquisition by Biogen Idec in February 2012); Avila Therapeutics, Inc. (until its acquisition by Celgene Corporation in February 2012); Nimbus Discovery, LLC; Edimer Pharmaceuticals; Ember Therapeutics, Inc. and BIND Therapeutics Inc. He currently serves on the board of directors of Blueprint Medicines, Bluebird Bio, Proclara Biosciences, Surface Oncology and Eleven Biotherapeutics, Inc. Dan received his BA in mathematics from Wesleyan University and his MBA from the Darden Graduate School of Business Administration at the University of Virginia.
Owen Hughes currently serves as the chief executive officer at Cullinan Oncology focused on oncological drug development. Prior to Cullinan, Mr. Hughes was the chief business officer and head of corporate development at Intarcia Therapeutics. Mr Hughes also served as director at Bain Capital Public Equity, a multibillion-dollar hedge fund. There, he comanaged public and private healthcare investments, including those in the biopharmaceutical, medtech and services segments. Mr. Hughes has over 16 years of Wall Street experience on both the buy and sell sides and serves on the board of both Radius Health (Nasdaq: RDUS) and Malin PLC (ESM: MLC).